INTOX, India Deploys Provantis Preclinical Software Solution

March 3, 2020 Off By BusinessWire

Provantis Selected to Improve Study Turnaround Times and Further Increase Data Quality at Pune Facility

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Instem, a leading provider of IT solutions to the global life sciences market, announced today that Indian Contract Research Organization, INTOX PVT Ltd. (INTOX), has deployed the Provantis® preclinical software solution to manage preclinical processes at its GLP certified research facility in Pune.

Founded in 1995, INTOX performs a wide range of study types, including Toxicological, Mutagenicity, Ecotoxicological and Chemical. Their client base includes leading pharmaceutical, crop protection/agrochemical, biotech, chemical and medical device organizations worldwide.

Provantis was selected following a detailed competitive evaluation and replaces existing manual processes at INTOX, delivering increased efficiencies in the collection, storage and reporting of preclinical data. Provantis enables INTOX to improve study turnaround time for their sponsors and will deliver further improvements in data quality, integrity and traceability.

Key Facts

The Co-Founders and Directors of INTOX, Dr. P.Y. Naik, Dr. M. P. Pore and Dr. Narendra Deshmukh were extremely impressed with the extensive capabilities of Provantis and its straightforward, intuitive functionality. They said “Provantis will dramatically reduce our study turnaround time and enable us to take our client service to the next level. Provantis is the gold standard globally and we are looking forward to realizing the transformational benefits that our investment in Provantis will bring.” Dr. Deshmukh asserted on the role Provantis will play in strengthening data integrity in the test facility, which will give a further boost to the client and regulator confidence that they already enjoy.

Jon Sparkes, Senior Director Sales, Europe & Asia, Instem, commented, “We are delighted to welcome INTOX to our growing client community within India and look forward to supporting them in their mission to provide high quality, reliable research and testing services in the field of product safety assessment to clients throughout the world.”

Instem anticipates that 2020 will be another growth year for the Provantis solution. This follows on from a sustained period of strong demand for Provantis across all its global markets during 2019, which saw the company welcome 13 new organizations to the Provantis client community.

About Intox

Headquartered in Pune, India, INTOX celebrates its 25th year of foundation in 2020. INTOX performs a wide range of safety assessment studies in the domains of Mammalian Toxicology, Mutagenicity, Environmental Toxicology, Biology and Chemistry, for Pharmaceutical, Crop Protection, Biotechnological, Chemical and Medical device organizations who wish to obtain National and International registration for their new products. In recent years the CRO has significantly expanded its strengths with additional infrastructure, manpower and equipment and made significant strides in its bioanalytical capabilities. The CRO considers the acquisition of Provantis as one of its strategic decisions in this direction.

For further information visit http://www.intoxlab.com/index.html

About Instem

Instem is a global provider of leading software solutions and services that are helping over 500 clients bring their life enhancing products to market faster. We enable clients in the life sciences to more efficiently collect, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world.

Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making, leading to safer, more effective products.

Instem supports its global roster of clients through offices in the United States, United Kingdom, France, Japan, China and India.

Contacts

Instem
Julie Jones (UK HQ)

[email protected]
Tel: +44 (0) 1785 825600